Abstract
We have investigated the effect of a series of bisphosphonates derived from fatty acids against Trypanosoma cruzi proliferation in in vitro assays. Some of these drugs proved to be potent inhibitors against the intracellular form of the parasite exhibiting IC50 values at the low micromolar level. As bisphosphonates are FDA clinically approved for treatment of bone resorption, their potential innocuousness makes them good candidates to control tropical diseases.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Bone Resorption / drug therapy
-
Diphosphonates / chemical synthesis
-
Diphosphonates / chemistry
-
Diphosphonates / pharmacology*
-
Diphosphonates / therapeutic use
-
Fatty Acids / chemistry*
-
Humans
-
Inhibitory Concentration 50
-
Parasitic Sensitivity Tests
-
Trypanocidal Agents / chemical synthesis
-
Trypanocidal Agents / chemistry
-
Trypanocidal Agents / pharmacology*
-
Trypanosoma cruzi / drug effects*
-
Trypanosoma cruzi / growth & development
-
United States
-
United States Food and Drug Administration
Substances
-
Diphosphonates
-
Fatty Acids
-
Trypanocidal Agents